These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301 [TBL] [Abstract][Full Text] [Related]
6. Induction of colitis in cftr-/- mice results in bile duct injury. Blanco PG; Zaman MM; Junaidi O; Sheth S; Yantiss RK; Nasser IA; Freedman SD Am J Physiol Gastrointest Liver Physiol; 2004 Aug; 287(2):G491-6. PubMed ID: 15064232 [TBL] [Abstract][Full Text] [Related]
7. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287 [TBL] [Abstract][Full Text] [Related]
8. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255 [TBL] [Abstract][Full Text] [Related]
9. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727 [TBL] [Abstract][Full Text] [Related]
10. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Angulo P; Jorgensen RA; Kowdley KV; Lindor KD Dig Dis Sci; 2008 Jun; 53(6):1716-20. PubMed ID: 17940903 [TBL] [Abstract][Full Text] [Related]
11. Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator-/- mice. Pall H; Zaman MM; Andersson C; Freedman SD J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):275-81. PubMed ID: 16540796 [TBL] [Abstract][Full Text] [Related]
12. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Tabibian JH; Gossard A; El-Youssef M; Eaton JE; Petz J; Jorgensen R; Enders FB; Tabibian A; Lindor KD Am J Ther; 2017; 24(1):e56-e63. PubMed ID: 24914504 [TBL] [Abstract][Full Text] [Related]
13. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231 [TBL] [Abstract][Full Text] [Related]
14. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Christensen B; Micic D; Gibson PR; Yarur A; Bellaguarda E; Corsello P; Gaetano JN; Kinnucan J; Rao VL; Reddy S; Singh S; Pekow J; Rubin DT Aliment Pharmacol Ther; 2018 Mar; 47(6):753-762. PubMed ID: 29377235 [TBL] [Abstract][Full Text] [Related]
15. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis]. Ahn DW Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856 [TBL] [Abstract][Full Text] [Related]
16. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. Jumpsen JA; Brown NE; Thomson AB; Paul Man SF; Goh YK; Ma D; Clandinin MT J Cyst Fibros; 2006 May; 5(2):77-84. PubMed ID: 16507353 [TBL] [Abstract][Full Text] [Related]
17. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Muir AJ; Levy C; Janssen HLA; Montano-Loza AJ; Shiffman ML; Caldwell S; Luketic V; Ding D; Jia C; McColgan BJ; McHutchison JG; Mani Subramanian G; Myers RP; Manns M; Chapman R; Afdhal NH; Goodman Z; Eksteen B; Bowlus CL; Hepatology; 2019 Feb; 69(2):684-698. PubMed ID: 30153359 [TBL] [Abstract][Full Text] [Related]
18. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. Stiehl A; Walker S; Stiehl L; Rudolph G; Hofmann WJ; Theilmann L J Hepatol; 1994 Jan; 20(1):57-64. PubMed ID: 8201224 [TBL] [Abstract][Full Text] [Related]
19. Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study. O'Connor MG; Thomsen K; Brown RF; Laposata M; Seegmiller A Prostaglandins Leukot Essent Fatty Acids; 2016 Oct; 113():46-49. PubMed ID: 27720040 [TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Talwalkar JA; Angulo P; Keach JC; Petz JL; Jorgensen RA; Lindor KD Am J Gastroenterol; 2005 Feb; 100(2):308-12. PubMed ID: 15667487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]